Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While Hexarelin is investigated for effects on GH secretion, cardiac protection, and muscle metabolism, with higher GH secretory potency than earlier GHRPs1929, Liraglutide is approved for type 2 diabetes and weight management, improving glycemic control and inducing weight loss through GLP-1–mediated insulinotropic, glucagonostatic, and appetite-suppressing actions6880.
While Hexarelin works as a potent synthetic hexapeptide (examorelin) that agonizes GHSR-1a to stimulate GH release and also binds CD36, influencing cardiovascular and metabolic pathways19212996, Liraglutide is a human GLP-1 analog with a single amino-acid substitution (Lys34→Arg) and a C16 palmitoyl fatty acid attached to Lys26 via a glutamate linker, producing a long-acting GLP-1 receptor agonist6880.
Hexarelin
GHSR
Liraglutide
GCG
Both peptides fall into a similar broad context as Hormone peptides, although the details of how they are used and discussed still diverge. Both are often discussed in Metabolic and endocrine contexts, while Hexarelin is more of a hormone peptide and Liraglutide is better described as a metabolic peptide. Both appear to work through Receptor agonist, but the functional emphasis still separates, with Hexarelin leaning toward Anabolic growth and Liraglutide leaning toward Metabolic regulation. Hexarelin has a more synthetic design origin, while Liraglutide is closer to synthetic analog background and their development context also differs, with Hexarelin in Preclinical development while Liraglutide is approved. Hexarelin takes the form of a linear peptide, whereas Liraglutide is closer to a peptide conjugate, Hexarelin carries d-amino acid substitution and amidation features, while Liraglutide instead reflects palmitoylation changes; while their sequence patterns also diverge, with Hexarelin showing protein-mimetic sequence features and Liraglutide showing alpha-helical domain features.